logo
Plus   Neg
Share
Email

Myriad Genetics Gets Rights To RAD51C Gene

Myriad Genetics, Inc. (MYGN) said Wednesday it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.

In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.

RAD51C was identified initially as a susceptibility gene for hereditary breast and ovarian cancer by members of the German Consortium for Hereditary Breast and Ovarian cancers in collaboration with pediatric hematologists and basic scientists predominantly located at the universities of Cologne, Dusseldorf and Munich.

Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Harley-Davidson Inc. (HOG) disclosed in a regulatory filing that it will be implementing a plan to shift production of motorcycles for the European Union destinations from the U.S. to its international facilities to avoid European Union's tariff. The company expects ramping-up production in international... Want to know when you will die? Google can tell. Google has tested an artificial intelligence or AI computer system that can predict whether hospital patients will pass away 24 hours after admission. Not just that, the system can also guess the length of a patient's stay in hospital and his chances of being readmitted. Piper Jaffray analyst Michael Olson said Monday that the video-game industry revenue could be 100 percent digital by 2022 and result in publisher margins being "dramatically higher." According to Olson, an all-digital video game world would be a tailwind for publishers like Activision Blizzard Inc., Electronic Arts Inc. and Take-Two Interactive Inc.
Follow RTT